Delcath Systems, Inc.

DCTH

US24661P8077

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
7.05 ^USD	+4.29%		-9.38%	+69.47%

05-28	Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors	CI
05-15	HC Wainwright Adjusts Price Target on Delcath Systems to $22 From $20, Maintains Buy Rating	MT

David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary

January 25, 2022 at 04:01 pm

Delcath Systems, Inc. announced that David Hoffman has been appointed as General Counsel and Corporate Secretary. Mr. Hoffman will also serve as Delcath's Chief Compliance Officer.

Latest news about Delcath Systems, Inc.

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors	05-28	CI
HC Wainwright Adjusts Price Target on Delcath Systems to $22 From $20, Maintains Buy Rating	05-15	MT
Transcript : Delcath Systems, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Stephens Starts Delcath Systems Wit Overweight Rating, $25 Price Target	05-14	MT
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q1 Revenue $3.1M, vs. Street Est of $2.2M	05-14	MT
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Delcath Systems Says Phase 3 Data on Hepzato Kit Published in Oncology Journal	05-06	MT
Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT	05-06	CI
Delcath Systems Amends Supply, Manufacturing Agreement With Synerx Pharma, Mylan Teoranta for Melphalan Hydrochloride	04-26	MT
HC Wainwright Adjusts Delcath Systems' Price Target to $20 From $18, Maintains Buy Rating	03-27	MT
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q4 Revenue $539,000, vs. Street Est of $550,000	03-26	MT
Transcript : Delcath Systems, Inc., Q4 2023 Earnings Call, Mar 26, 2024	03-26
Delcath Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
North American Morning Briefing : Markets Steady -2-	03-26	DJ
Delcath Systems, Inc. announced that it has received $7.00111 million in funding	03-19	CI
Delcath Systems Names Chief Operating Officer	03-19	MT
Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer	03-18	CI
Delcath Systems, Inc. announced that it expects to receive $7.00111 million in funding	03-14	CI
Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO? KIT (melphalan/Hepatic Delivery System)	02-22	CI
Delcath Systems, Inc. Announces Executive Changes	02-14	CI
Delcath Systems Receives Permanent J-Code for HEPZATO? (melphalan/Hepatic Delivery System) Effective April 1, 2024	01-31	CI
Delcath Systems Launches Hepzato Kit in US for Treatment of Metastatic Uveal Melanoma	01-16	MT
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit?	01-16	CI
Delcath Systems Insider Bought Shares Worth $148,800, According to a Recent SEC Filing	11-20	MT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Delcath Systems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.05 USD

Average target price

21.2 USD

Spread / Average Target

+200.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
DELCATH SYSTEMS, INC.	+69.47%	196M
SONOVA HOLDING AG	+3.79%	18.79B
COCHLEAR LIMITED	+8.00%	14.03B
DEMANT A/S	+11.15%	10.41B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-20.38%	1.99B
EMBLA MEDICAL HF.	+3.10%	1.76B
ANGELALIGN TECHNOLOGY INC.	+8.31%	1.33B
MODERN DENTAL GROUP LIMITED	+6.05%	552M
ANGEL ROBOTICS CO., LTD.	-.--%	421M
INTEGRUM AB	+11.28%	88.9M

Medical Prosthetics

Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Medical Equipment, Supplies & Distribution

David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary

Latest news about Delcath Systems, Inc.

Chart Delcath Systems, Inc.

Company Profile

Income Statement Evolution

Ratings for Delcath Systems, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Prosthetics